DOCSLIB.ORG

TIANJIN ZHONG XIN PHARMACEUTICAL GROUP CORPORATION LIMITED (Company Registration No.: 120000000004711) (Incorporated in the People’S Republic of China (The “PRC”))

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
TIANJIN ZHONG XIN PHARMACEUTICAL GROUP CORPORATION LIMITED (Company Registration No.: 120000000004711) (Incorporated in the People’S Republic of China (The “PRC”)) TIANJIN ZHONG XIN PHARMACEUTICAL GROUP CORPORATION LIMITED (Company Registration No.: 120000000004711) (Incorporated in the People’s Republic of China (the “PRC”)) Resolutions Passed at the 8th Board Meeting for FY2013 The board of directors of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (the “Board”) collectively and individually accept full responsibility for the accuracy of the information given in this announcement, and confirm after making all reasonable enquiries that, to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading. Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (the “Company”) had on 26 August 2013 issued a notice of board meeting to its directors in respect of the 8th Board Meeting for FY2013, and the said board meeting was duly convened on 5 September 2013 and the following resolutions were discussed and passed by the full board of 9 directors. The said meeting was convened in compliance with the applicable Companies law, Securities Law and the Memorandum & Articles of Association of the Company, and the following resolutions were passed: (1) That, the initiation of the project of the proposed investment in Zhong Xin Pharmaceutical Bozhou Industry Park (the “Project”) be approved (Please refer to Appendix 1 for the details of the Project); and (2) That, the proposed appointment of Ruihua Certified Public Accountants as PRC auditors of the Company. The above resolution No. 2 is subject to approval from the shareholders of the Company (the “Shareholders”). Pursuant to the relevant requirements under the applicable Companies law, Securities Law and the Memorandum & Articles of Association of the Company, the Board proposes to convene an extraordinary general meeting (“EGM”) for Shareholders to consider and approve the above resolution No. 2. A notice convening the EGM of the Company will be dispatched to the Shareholders in due course. By order of the Board 5 September 2013 Appendix 1 THE PROPOSED INVESTMENT IN ZHONG XIN PHARMACENTICAL BOZHOU INDUSTRY PARK 1. INTRODUCTION The Company intends to set up Zhong Xin Pharmaceutical Bozhou Industry Park (the “Project”). The Project has been approved at the 2nd Board Meeting on 28 March 2013 and announced on 30 March 2013. Following further progress, additional details of the Project have been submitted to the 8th Board Meeting for further approval. 2. DETAILS OF THE PROJECT 2.1 Name Tianjin Zhong Xin Bozhou Industry Park (the official name is subject to the registration) 2.2 Location Industry Park, Qiaocheng District, Bozhou City, Anhui Province 2.3 Investment Amount RMB 200 million 2.4 Project Process 2.4.1 Land Purchase The Company will purchase land in the Industry Park and then set up Tianjin Zhong Xin Pharmaceutical Bozhou Industry Park (the “Zhong Xin Bozhou Industry Park”). 2.4.2 Establishment of Tianjin Da Ren Tang (Bozhou) Chinese Medicine Yinpian Co., Ltd (the “Da Ren Tang Yinpian”) (the official name is subject to the business registration) Da Ren Tang Yinpian, with a registered capital of up to RMB 30 million, is jointly founded by the Company, Anhui Jingquan Group Corporation Limited (the ”Anhui Jingquan”) and Tianjin Yuliang Investment Co., Ltd (the “Tianjin Yuliang”). The Company will invest RMB 18 million, representing 60% of the share capital in Da Ren Tang Yinpian and it has no interest relationship with Anhui Jingquan and Tianjin Yuliang. 2.4.3 Establishment of Tianjin Da Ren Tang (Bozhou) Pharmaceutical Co., Ltd (the “Da Ren Tang Pharmaceutical”) (the official name is subject to the business registration) Da Ren Tang Pharmaceutical, with a registered capital of up to RMB 70 million, is jointly founded by the Company, Anhui Jingquan Group Corporation Limited and Tianjin Yuliang Investment Co., Ltd. The Company will invest RMB 42 million, representing 60% of the share capital in Da Ren Tang Pharmaceutical and it has no interest relationship with Anhui Jingquan and Tianjin Yuliang. 2.4.4 Business Scope The business scope of Zhong Xin Bozhou Industry Park is: (a) production and sales of Chinese medicine patent prescriptions; (b) production and sales of herbal extracts; (c) production and sales of Chinese medicine (d) purchase of agricultural and derivative products; (e) production and sales of Chinese medicine Yinpian; and (f) production and sales of health care products. 3. DETAILS OF ZHONG XIN BOZHOU INDUSTRY PARK Bozhou City is located in the northwest of Anhui Province and the junction of Jiangsu, Shandong, Henan and Anhui provinces. It is famous for being one of the four ancient Chinese medicine bases. Bozhou City has a Chinese medicine planting area of nearly 100 hectares, representing 10% of the planting area in the nation, and accounts for one third of the annual national production of Chinese medicine. It also accounts for one fourth of the annual national sales of Chinese medicine. Qiaocheng District has long been reputed as the capital of Chinese medicine. It has the largest national "China (Bozhou) Chinese herbal medicine trade centre” and cultivates wild herbs of 171 species and 410 varieties. By setting up a herbal medicine business centre in Bozhou City, the Company can ensure a consistent supply of raw materials for manufacturing plant, and can expand its market reach as well. 4. RATIONALE FOR THE PROJECT The directors of the Company are of the view that the Project is important for the Company’s development, for the following reasons: 4.1 Promote the Company's long-term development strategy The Company is marching forward to its strategic target of being a pharmaceutical listed company with top-grade performance. To achieve this goal, it requires the company not only to adjust product structure, optimise marketing strategy, and enhance the management structure, but it also requires investment diversification and market expansion. 4.2 Promote the expansion of the Chinese medicine industry to guarantee the Company’s continued production Zhong Xin Bozhou Industry Park can make full use of the geographical advantages of Bozhou City as the distribution centre of Chinese herbal medicine. With sufficient supply of herbs, the Company is able to further develop production, extraction and processing of Yinpian and play a positive role in the production of medicines. 4.3 Reduce the Company’s costs and enhance its market competitiveness The favourable investment environment of Qiaocheng Industry Park can reduce the Company’s costs in land, labour and raw materials, which will enhance its market competitiveness and satisfy its investment requirements. 4.4 Optimise the Company’s industrial plan and achieve its overall development The Company’s overall development strategy is to build industry parks in the north and south of the PRC. The Northern Industry Park, located in the Tianjin Development Zone, is known as a modern medicine centre. Equipped with sophisticated hardware, it focuses on technology research and innovation and aims to produce high value-added, high-end products. While the Southern Industry Park is planning to make use of cost advantage and focus on generic drugs production, herbal medicines storage and management. With the newly-built Zhong Xin Bozhou Industry Park, the Company would extend its industrial chains and further optimise its industrial plan. .
Load more

Recommended publications
  • On the Local Political Economy of Rural Urbanisation in China, In: Journal of Current Chinese Affairs, 45, 1, 109–139
    Journal of Current Chinese Affairs China aktuell Topical Issue: Policy Implementation in the New Socialist Countryside Guest Editor: René Trappel Meyer-Clement, Elena (2016), The Great Urban Leap? On the Local Political Economy of Rural Urbanisation in China, in: Journal of Current Chinese Affairs, 45, 1, 109–139. URN: http://nbn-resolving.org/urn/resolver.pl?urn:nbn:de:gbv:18-4-9488 ISSN: 1868-4874 (online), ISSN: 1868-1026 (print) The online version of this article and the other articles can be found at: <www.CurrentChineseAffairs.org> Published by GIGA German Institute of Global and Area Studies, Institute of Asian Studies and Hamburg University Press. The Journal of Current Chinese Affairs is an Open Access publication. It may be read, copied and distributed free of charge according to the conditions of the Creative Commons Attribution-No Derivative Works 3.0 License. To subscribe to the print edition: <[email protected]> For an e-mail alert please register at: <www.CurrentChineseAffairs.org> The Journal of Current Chinese Affairs is part of the GIGA Journal Family, which also includes Africa Spectrum, Journal of Current Southeast Asian Affairs and Journal of Politics in Latin America: <www.giga-journal-family.org>. Journal of Current Chinese Affairs 1/2016: 109–139 The Great Urban Leap? On the Local Political Economy of Rural Urbanisation in China Elena MEYER-CLEMENT Abstract: This paper provides insights into the local political econ- omy of China’s current in situ urbanisation as compared to the 1980s and 1990s, focusing on the role played by county and township gov- ernments in shaping urbanisation in their localities.
    [Show full text]
  • Table of Codes for Each Court of Each Level
    Table of Codes for Each Court of Each Level Corresponding Type Chinese Court Region Court Name Administrative Name Code Code Area Supreme People’s Court 最高人民法院 最高法 Higher People's Court of 北京市高级人民 Beijing 京 110000 1 Beijing Municipality 法院 Municipality No. 1 Intermediate People's 北京市第一中级 京 01 2 Court of Beijing Municipality 人民法院 Shijingshan Shijingshan District People’s 北京市石景山区 京 0107 110107 District of Beijing 1 Court of Beijing Municipality 人民法院 Municipality Haidian District of Haidian District People’s 北京市海淀区人 京 0108 110108 Beijing 1 Court of Beijing Municipality 民法院 Municipality Mentougou Mentougou District People’s 北京市门头沟区 京 0109 110109 District of Beijing 1 Court of Beijing Municipality 人民法院 Municipality Changping Changping District People’s 北京市昌平区人 京 0114 110114 District of Beijing 1 Court of Beijing Municipality 民法院 Municipality Yanqing County People’s 延庆县人民法院 京 0229 110229 Yanqing County 1 Court No. 2 Intermediate People's 北京市第二中级 京 02 2 Court of Beijing Municipality 人民法院 Dongcheng Dongcheng District People’s 北京市东城区人 京 0101 110101 District of Beijing 1 Court of Beijing Municipality 民法院 Municipality Xicheng District Xicheng District People’s 北京市西城区人 京 0102 110102 of Beijing 1 Court of Beijing Municipality 民法院 Municipality Fengtai District of Fengtai District People’s 北京市丰台区人 京 0106 110106 Beijing 1 Court of Beijing Municipality 民法院 Municipality 1 Fangshan District Fangshan District People’s 北京市房山区人 京 0111 110111 of Beijing 1 Court of Beijing Municipality 民法院 Municipality Daxing District of Daxing District People’s 北京市大兴区人 京 0115
    [Show full text]
  • Appendix Iii: Property Valuation Report
    THIS DOCUMENT IS IN DRAFT FORM, INCOMPLETE AND SUBJECT TO CHANGE AND THAT THE INFORMATION MUST BE READ IN CONJUNCTION WITH THE SECTION HEADED “WARNING” ON THE COVER OF THIS DOCUMENT. APPENDIX III PROPERTY VALUATION REPORT The following is the text of a letter, summary of values and valuation certificates prepared for the purpose of incorporation in this document received from Jones Lang LaSalle Corporate Appraisal and Advisory Limited, an independent valuer, in connection with its valuation as at April 30, 2021 of the property interests held by Sanxun Holdings Group Limited. [Date] The Board of Directors Sanxun Holdings Group Limited [address] Dear Sirs, In accordance with your instructions to value the property interests held by Sanxun Holdings Group Limited (the “Company”) and its subsidiaries (hereinafter together referred to as the “Group”) in the People’s Republic of China (the “PRC”), we confirm that we have carried out inspections, made relevant enquiries and searches and obtained such further information as we consider necessary for the purpose of providing you with our opinion on the market values of the property interests as at April 30, 2021 (the “valuation date”). Our valuation was carried out on a market value basis. Market value is defined as “the estimated amount for which an asset or liability should exchange on the valuation date between a willing buyer and a willing seller in an arm’s-length transaction after proper marketing and where the parties had each acted knowledgeably, prudently and without compulsion”. We have valued the property interests in Group I which are held for sale by the Group, property interests in Group III which are held for future development by the Group by the comparison approach assuming sale of the property interests in their existing state with the benefit of immediate vacant possession and by making reference to comparable sales transactions as available in the market.
    [Show full text]
  • 20180313—EN.Pdf
    AN OVERVIEW OF THE CCP'S REPRESSION AND PERSECUTION OF THE CHURCH OF ALMIGHTY GOD TABLE OF CONTENTS General Introduction......................................................................................................... 1 15 Cases of Death by Persecution ................................................................................... 4 5 Cases of Torture Resulting in Disability ...................................................................... 11 8 Cases of Imprisonment ................................................................................................ 14 General Introduction The Origin and Development of The Church of Almighty God The Church of Almighty God (CAG) is a Christian Church founded in China in 1991. The Church came into being due to the appearance of Almighty God—the second coming of the Lord Jesus—and the truths He expressed in The Word Appears in the Flesh, fulfilling the prophecy of the Lord Jesus, “For as the lightning comes out of the east, and shines even to the west; so shall also the coming of the Son of man be” (Matthew 24:27). Accordingly, the Church is referred to by various Christian denominations as “Eastern Lightning.” The name “Almighty God” fulfills the prophecy in the Book of Revelation, “I am Alpha and Omega, the beginning and the ending, said the Lord, which is, and which was, and which is to come, the Almighty” (Revelation 1:8). Christian doctrine originates from the Bible. The doctrine of The Church of Almighty God originates from the Old and New Testaments of the Bible, as well as The Word Appears in the Flesh expressed by Almighty God—the second coming of Lord Jesus. The Word Appears in the Flesh fulfills the prophecies of “the scroll opened by the lamb” (Revelation 5:1-5) and “what the Spirit said to the churches” (Revelation 2:7, 11; 3:6).
    [Show full text]
  • SUNAC CHINA HOLDINGS LIMITED 融創中國控股有限公司 (Incorporated in the Cayman Islands with Limited Liability) (Stock Code: 01918)
    Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no 14.88 responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. SUNAC CHINA HOLDINGS LIMITED 融創中國控股有限公司 (Incorporated in the Cayman Islands with limited liability) (Stock Code: 01918) (1) VERY SUBSTANTIAL ACQUISITION ENTERING INTO OF FRAMEWORK AGREEMENT IN RELATION TO THE COOPERATION OF TARGET PROJECT COMPANIES AND TARGET HOTEL ASSETS AND (2) RESUMPTION OF TRADING IN SHARES THE COOPERATION The Board is pleased to announce that, on 10 July 2017, Sunac Real Estate, an indirect wholly-owned subsidiary of the Company as the buyer, and Dalian Wanda Commercial Properties as the seller entered into the Framework Agreement, pursuant to which the Buyer agreed to acquire, and the Seller agreed to dispose of 91% equity interest of the 13 cultural and tourism project companies in the PRC (i.e. the Target Project Companies) and 100% interest of the 76 city hotels (i.e. the Target Hotel Assets) at the consideration of approximately RMB29,575,000,000 and RMB33,595,260,800 respectively. Thus, the total consideration for the Cooperation is approximately RMB63,170,260,800. Before completion of the Cooperation, the Seller held 100% equity interest of the Target Project Companies and 100% interest of the Target Hotel Assets. After completion of the Cooperation, the Buyer will hold 91% equity interest of the Target Project Companies and 100% interest of the Target Hotel Assets, while the Seller will continue to hold 9% equity interest of the Target Project Companies.
    [Show full text]
  • 中國內地指定醫院列表 出版日期: 2019 年 7 月 1 日 Designated Hospital List in Mainland China Published Date: 1 Jul 2019
    中國內地指定醫院列表 出版日期: 2019 年 7 月 1 日 Designated Hospital List in Mainland China Published Date: 1 Jul 2019 省 / 自治區 / 直轄市 醫院 地址 電話號碼 Provinces / 城市/City Autonomous Hospital Address Tel. No. Regions / Municipalities 中國人民解放軍第二炮兵總醫院 (第 262 醫院） 北京 北京 西城區新街口外大街 16 號 The Second Artillery General Hospital of Chinese 10-66343055 Beijing Beijing 16 Xinjiekou Outer Street, Xicheng District People’s Liberation Army 中國人民解放軍總醫院 (第 301 醫院） 北京 北京 海澱區復興路 28 號 The General Hospital of Chinese People's Liberation 10-82266699 Beijing Beijing 28 Fuxing Road, Haidian District Army 北京 北京 中國人民解放軍第 302 醫院 豐台區西四環中路 100 號 10-66933129 Beijing Beijing 302 Military Hospital of China 100 West No.4 Ring Road Middle, Fengtai District 中國人民解放軍總醫院第一附屬醫院 (中國人民解 北京 北京 海定區阜成路 51 號 放軍 304 醫院） 10-66867304 Beijing Beijing 51 Fucheng Road, Haidian District PLA No.304 Hospital 北京 北京 中國人民解放軍第 305 醫院 西城區文津街甲 13 號 10-66004120 Beijing Beijing PLA No.305 Hospital 13 Wenjin Street, Xicheng District 北京 北京 中國人民解放軍第 306 醫院 朝陽區安翔北里 9 號 10-66356729 Beijing Beijing The 306th Hospital of PLA 9 Anxiang North Road, Chaoyang District 中國人民解放軍第 307 醫院 北京 北京 豐台區東大街 8 號 The 307th Hospital of Chinese People’s Liberation 10-66947114 Beijing Beijing 8 East Street, Fengtai District Army 中國人民解放軍第 309 醫院 北京 北京 海澱區黑山扈路甲 17 號 The 309th Hospital of Chinese People’s Liberation 10-66775961 Beijing Beijing 17 Heishanhu Road, Haidian District Army 中國人民解放軍第 466 醫院 (空軍航空醫學研究所 北京 北京 海澱區北窪路北口 附屬醫院） 10-81988888 Beijing Beijing Beiwa Road North, Haidian District PLA No.466 Hospital 北京 北京 中國人民解放軍海軍總醫院 (海軍總醫院） 海澱區阜成路 6 號 10-66958114 Beijing Beijing PLA Naval General Hospital 6 Fucheng Road, Haidian District 北京 北京 中國人民解放軍空軍總醫院 (空軍總醫院） 海澱區阜成路 30 號 10-68410099 Beijing Beijing Air Force General Hospital, PLA 30 Fucheng Road, Haidian District 中華人民共和國北京市昌平區生命園路 1 號 北京 北京 北京大學國際醫院 Yard No.1, Life Science Park, Changping District, Beijing, 10-69006666 Beijing Beijing Peking University International Hospital China, 東城區南門倉 5 號(西院) 5 Nanmencang, Dongcheng District (West Campus) 北京 北京 北京軍區總醫院 10-66721629 Beijing Beijing PLA.
    [Show full text]
  • Listing of Global Companies with Ongoing Government Activity
    COMPANY LINE OF BUSINESS TICKER B & B MICROSCOPES, LTD. PROFESSIONAL EQUIPMENT, NEC, NSK B & C NUTRITIONAL PRODUCTS INC MEDICINALS AND BOTANICALS, NSK B & H FOTO & ELECTRONICS CORP. CAMERA AND PHOTOGRAPHIC SUPPLY STORES B A DISTRIBUTORS PHARMACEUTICAL PREPARATIONS B B TECH HERBAL LIMITED MEDICINALS AND BOTANICALS, NSK B BRAUN MEDICAL SA MEDICINALS AND BOTANICALS, NSK B C GROUP LLC ELECTRICAL WORK, NSK B C N PLC PHARMACEUTICAL PREPARATIONS B C PHARMA AGENCIES PHARMACEUTICAL PREPARATIONS B D MEDICAL SYSTEM PHARMACEUTICAL PREPARATIONS B D N PHARMACEUTICALS PHARMACEUTICAL PREPARATIONS B D PHARMACEUTICALS PHARMACEUTICAL PREPARATIONS B D R PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED PHARMACEUTICAL PREPARATIONS B D S DRUGS & CHEMICALS PHARMACEUTICAL PREPARATIONS B G DISTRIBUTORS PHARMACEUTICAL PREPARATIONS B G HERBAL MEDICINALS AND BOTANICALS, NSK B G P HEALTHCARE PRIVATE LIMITED PHARMACEUTICAL PREPARATIONS B H C AYURVEDIC RESEARCH LAB PRIVATE LIMITED MEDICINALS AND BOTANICALS, NSK B H CHEMICAL WORKS PRIVATE LIMITED PHARMACEUTICAL PREPARATIONS B H P AYURVEDIC PRIVATE LIMITED MEDICINALS AND BOTANICALS, NSK B I CHEM BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC B I R PHARMACEUTICALS PHARMACEUTICAL PREPARATIONS B J C CORPORATE HEALTH SERVICES OFFICES AND CLINICS OF MEDICAL DOCTORS, N B J INTERNATIONAL PHARMACEUTICAL PREPARATIONS B JAIN PHARMACEUTICALS PVT. LTD. PHARMACEUTICAL PREPARATIONS B K PHARM & PHARM PRIVATE LIMITED PHARMACEUTICAL PREPARATIONS B K SANITATION BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC B L H TRADING CO LTD PHARMACEUTICAL PREPARATIONS B M ANTIBIOTICS PHARMACEUTICAL PREPARATIONS B M C PHARMACEUTICALS PHARMACEUTICAL PREPARATIONS B M KRAMER & COMPANY INC METALS SERVICE CENTERS AND OFFICES B M PHARMACEUTICALS PHARMACEUTICAL PREPARATIONS B M S CHEMIE PHARMACEUTICAL PREPARATIONS B M S CHEMIE PHARMACEUTICAL PREPARATIONS B NEVINS LTD. WOOD OFFICE FURNITURE, NSK B O S TEMPORARIES INC HELP SUPPLY SERVICES B P L NOIR PHARMACEUTICAL PREPARATIONS B P L PHARMACEUTICALS PRIVATE LIMITED PHARMACEUTICAL PREPARATIONS B P S LABORATORIOS INDUSTRIAL COMERCIAL FARMACEUTICA S.R.L.
    [Show full text]
  • CHINA the Church of Almighty God: Prisoners Database (1663 Cases)
    CHINA The Church of Almighty God: Prisoners Database (1663 cases) Prison term: 15 years HE Zhexun Date of birth: On 18th September 1963 Date and place of arrest: On 10th March 2009, in Xuchang City, Henan Province Charges: Disturbing social order and using a Xie Jiao organization to undermine law enforcement because of being an upper-level leader of The Church of Almighty God in mainland China, who was responsible for the overall work of the church Statement of the defendant: He disagreed with the decision and said what he believed in is not a Xie Jiao. Court decision: In February 2010, he was sentenced to 15 years in prison by the Zhongyuan District People’s Court of Zhengzhou City, Henan Province. Place of imprisonment: No. 1 Prison of Henan Province Other information: He was regarded by the Chinese authorities as a major criminal of the state and had long been on the wanted list. To arrest him, authorities offered 500,000 RMB as a reward to informers who gave tips leading to his arrest to police. He was arrested at the home of a Christian in Xuchang City, Henan Province. Based on the information from a Christian serving his sentence in the same prison, HE Zhexun was imprisoned in a separate area and not allowed to contact other prisoners. XIE Gao, ZOU Yuxiong, SONG Xinling and GAO Qinlin were arrested in succession alongside him and sentenced to prison terms ranging from 11 to 12 years. Source: https://goo.gl/aGkHBj Prison term: 14 years MENG Xiumei Age: Forty-one years old Date and place of arrest: On 14th August 2014, in Xinjiang Uyghur Autonomous Region Charges: Using a Xie Jiao organization to undermine law enforcement because of being a leader of The Church of Almighty God and organizing gatherings for Christians and the work of preaching the gospel in Ili prefecture Statement of the defendant: She claimed that her act did not constitute crimes.
    [Show full text]
  • Differential Diagnosis of Coronavirus Disease 2019 from Community
    Liu et al. Infectious Diseases of Poverty (2020) 9:118 https://doi.org/10.1186/s40249-020-00737-9 RESEARCH ARTICLE Open Access Differential diagnosis of coronavirus disease 2019 from community-acquired-pneumonia by computed tomography scan and follow- up Kai-Cai Liu1, Ping Xu2*, Wei-Fu Lv3* , Lei Chen4, Xiao-Hui Qiu5, Jin-Long Yao6, Jin-Feng Gu4,BoHu7 and Wei Wei3 Abstract Objective: Coronavirus disease 2019 (COVID-19) is currently the most serious infectious disease in the world. An accurate diagnosis of this disease in the clinic is very important. This study aims to improve the differential ability of computed tomography (CT) to diagnose COVID-19 and other community-acquired pneumonias (CAPs) and evaluate the short-term prognosis of these patients. Methods: The clinical and imaging data of 165 COVID-19 and 118 CAP patients diagnosed in seven hospitals in Anhui Province, China from January 21 to February 28, 2020 were retrospectively analysed. The CT manifestations of the two groups were recorded and compared. A correlation analysis was used to examine the relationship between COVID-19 and age, size of lung lesions, number of involved lobes, and CT findings of patients. The factors that were helpful in diagnosing the two groups of patients were identified based on specificity and sensitivity. Results: The typical CT findings of COVID-19 are simple ground-glass opacities (GGO), GGO with consolidation or grid-like changes. The sensitivity and specificity of the combination of age, white blood cell count, and ground- glass opacity in the diagnosis of COVID-19 were 92.7 and 66.1%, respectively.
    [Show full text]
  • Annual Report 2018
    Annual Report 2018 Anhui Gujing Distillery Company Limited April 2019 Gujinggong Liquor Aged Original Liquor Annual Report 2018 Part I Important Notes The Board of Directors (or the “Board”), the Supervisory Committee as well as the directors, supervisors and senior management of Anhui Gujing Distillery Company Limited (hereinafter referred to as the “Company”) hereby guarantee the factuality, accuracy and completeness of the contents of this Report and its summary, and shall be jointly and severally liable for any misrepresentations, misleading statements or material omissions therein. Liang Jinhui, the legal representative, Ye Changqing, the Chief Accountant, and Zhu Jiafeng, the head of the financial department (equivalent to financial manager) hereby guarantee that the financial statements carried in this Report are factual, accurate and complete. All the Company’s directors have attended the Board meeting for the review of this Report and its summary. Any plans for the future and other forward-looking statements mentioned in this Report shall NOT be considered as absolute promises of the Company to investors. Investors, among others, shall be sufficiently aware of the risk and shall differentiate between plans/forecasts and promises. Again, investors are kindly reminded to pay attention to possible investment risks. The Board has approved a final dividend plan as follows: based on the Company’s total shares on 31 December 2018, a cash dividend of RMB15.00 (tax inclusive) per 10 shares is to be distributed to the shareholders, with no bonus issue from either profit or capital reserves. This Report and its summary have been prepared in both Chinese and English.
    [Show full text]
  • Extraction and Analysis of Traditional Chinese Medicine Crops Based on Multitemporal High Resolution Data-Taking Qiaocheng District of Bozhou As an Example
    The International Archives of the Photogrammetry, Remote Sensing and Spatial Information Sciences, Volume XLII-3, 2018 ISPRS TC III Mid-term Symposium “Developments, Technologies and Applications in Remote Sensing”, 7–10 May, Beijing, China EXTRACTION AND ANALYSIS OF TRADITIONAL CHINESE MEDICINE CROPS BASED ON MULTITEMPORAL HIGH RESOLUTION DATA-TAKING QIAOCHENG DISTRICT OF BOZHOU AS AN EXAMPLE Hong Yu1, Jianjun He 1, *, Huizhen Zhou1,2,Feng Guan1,Longlong Li1,Baiyang Ren1，Zhiyong Wang3 1Twenty First Century Aerospace Technology Co., Ltd., Beijing, China - (yuhong, hejj, zhouhz, guanfeng, lill,renby) @21at.com.cn 2State Key Laboratory of Earth Surface Processes and Resource Ecology, School of Natural Resources, Faculty of Geographical Science, Beijng Normal University, Beijing, China 3Beijing Engineering Research Center of Small Satellite Remote Sensing Information, Beijing, China - [email protected] KEY WORDS: Multitemporal, Remote,SensingData, Chinese Medicine Crops, Interpretation, Information Extraction ABSTRACT: Remote sensing technology has become an important method to rapidly acquireing of planting layout and composition of regional crops.It is very important to accurately master the planting area of Chinese medicine crops in the Characteristic planting area because it relations to accurately master the cultivation of Chinese medicine crops, formulate related policies and adjustment of crop planting structure.The author puts forward a method of using remote sencing technology for momitoring Chinese medicine which has good applicability and generalization. This paper took Qiaocheng District of Bozhou as an example to Verify the feasibility of the method,providing a reference for solving the problem of interpretation and extraction of Chinese medicinal materials in the region. 1. INSTRUCTION cultivation and monitoring of Chinese medicine crops by means of remote sensing.
    [Show full text]
  • Global Offering
    Sanxun Holdings Group Limited 三巽控股集團有限公司 (Incorporated in the Cayman Islands with limited liability) Stock Code: 6611 GLOBAL OFFERING Sole Sponsor and Sole Global Coordinator Joint Bookrunners IMPORTANT If you are in any doubt about any of the contents of this prospectus, you should seek independent professional advice. The application for the Hong Kong Offer Shares will commence on Wednesday, June 30, 2021 up to Monday, July 12, 2021, being longer than the normal market practice of 3.5 days. Sanxun Holdings Group Limited 三巽控股集團有限公司 (Incorporated in the Cayman Islands with limited liability) GLOBAL OFFERING Number of Offer Shares under : 165,000,000 Offer Shares (subject to the Global Offering the Over-allotment Option) Number of Hong Kong Offer Shares : 16,500,000 Offer Shares (subject to adjustment) Number of International Offer Shares : 148,500,000 Offer Shares (subject to adjustment and the Over-allotment Option) Maximum Offer Price : HK$5.20 per Offer Share, plus brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong dollars and subject to refund) Nominal value : HK$0.00001 per Offer Share Stock code : 6611 Sole Sponsor and Sole Global Coordinator Joint Bookrunners CRIC SECURITIES CO. LTD Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this prospectus, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this prospectus.
    [Show full text]